u/whodoesntlovedogs

I literally did a back & forth 8 journey to test drive this beauty in PA. Unlike any other car I have ever driven before and the ride was super smooth, specially on sport. I just couldn’t justify in my head paying a total of $64.5k for a 2026 XDrive (only 2k miles). I would be more comfortable around $52-54k range.

1st Image: Tee by Loewe, jeans by Madewell, Sunglasses by Gentle Monster and Jordans.

2nd Image: Tux and shoes by Suit Supply. Shirt by Armani.

Glasses by Warby Parker, Shirt by Hugo Boss, Jeans by A&F, Watch by Fossil and Shoes by Zara. Camera by Nikon 📸

Overall, the experience was decent and the food was great and so were the drinks. However, I would place it below Le Blanc in Cabos and would still recommend Atelier.

Top by Abercrombie, jeans by Uniqlo x JW Anderson, shoes by Zara, silver chain by Yurman and undershirt by Perry Ellis.

Shirt by Zara and tee by Uniqlo. And nope, this is not AI. I just happen to take nice pictures 👍🏼

This stock is not new to me and over the past few years, thanks to its volatility I have made a decent gain. At these prices, it’s my biggest yolo across several accounts. And yes I know, will charge my phone soon.

Bull Case
1. They are still growing fast
Despite the selloff, revenue still grew 21% YoY in Q1 2026 to ~$174M.
That matters because:
This is not a collapsing business
Demand for organ transplants continues rising
TMDX still dominates the warm organ perfusion category
The market punished the stock because margins compressed — not because the core business stopped growing.

2. The moat is real
TMDX is no longer just a device company:
OCS platform
Logistics network
Aircraft fleet
Clinical transplant ecosystem
NOP (National OCS Program)
That vertical integration is difficult to replicate.
Hospitals are unlikely to switch vendors once workflows, surgeons, and logistics are embedded into transplant operations.

3. Europe could become a second growth engine
Management is investing aggressively into Europe and transplant logistics expansion, including PAD Aviation.
If Europe adoption works:
Revenue growth could reaccelerate
Market may reward TMDX with premium multiples again
Long-term TAM expands significantly

4. The market may be overreacting to temporary margin compression
A lot of the Q1 pain came from:
Scaling costs
Clinical trial investment
Logistics expansion
Higher operating expenses
If margins stabilize later in 2026:
Sentiment can reverse quickly
Analysts may start upgrading again
Growth + profitability combo returns

5. Valuation has compressed dramatically
Earlier this year the market priced TMDX like a “perfect execution” story.
Now:
PE compressed hard
Expectations reset
Fear elevated
Sometimes the best long-term entries happen after:
first major earnings miss
analyst downgrades
momentum funds exiting

Bear Case
1. Margin deterioration could be structural
This is the biggest concern.
Revenue grew 21%, but:
EPS dropped massively
Operating margin fell from ~19% to ~7.6%
If logistics becomes permanently expensive:
TMDX may never regain prior profitability
Premium valuation disappears
Stock may stay range-bound for years

2. Analysts lost confidence
Several firms cut targets after earnings:
Oppenheimer downgraded to Market Perform
Stifel cut PT to $85
TD Cowen lowered to $120
Wall Street narrative shifted from:
“hypergrowth medical disruptor” to “execution and profitability concerns”
Narrative shifts matter a lot for momentum stocks.

3. Clinical program delays
The ENHANCE and DENOVO programs saw enrollment delays.
If adoption slows:
Growth multiple compresses further
Expansion assumptions weaken
Future guidance may come down

4. Concentration risk
TMDX is still heavily dependent on:
transplant growth
reimbursement
logistics execution
regulatory momentum
One major operational issue or safety concern could materially hurt the stock.

5. Stock technical damage is significant
The chart broke badly after earnings.
Momentum names that break:
often overshoot downward
take months to rebuild confidence
can remain volatile even with good fundamentals

Updated Price Targets (12–24 Months)
Bear Scenario
$45–55
Happens if:
margins keep deteriorating
growth slows below 20%
guidance cuts appear
institutional selling continues
This would likely imply the market fully reprices TMDX as a slower-growth medtech company.

Base Case
$85–100
Happens if:
revenue growth stays ~20–25%
margins stabilize
Europe expansion progresses
sentiment recovers gradually
This is probably the most realistic medium-term recovery range right now.

Bull Case (will start selling around here)
$120–150+
Happens if:
margins recover materially
Europe/NOP expansion succeeds
kidney program gains traction
transplant volumes accelerate
Wall Street regains confidence
At that point the market would likely rerate TMDX back toward premium-growth medtech valuations.

What I’d Watch Next
The next 2–3 quarters are critical.
The market no longer cares only about revenue growth.